American Oriental Bioengineering Honorably Elected a Top 20 Most Competitive Public Pharmaceutical Company in China
July 21 2009 - 9:00AM
PR Newswire (US)
NEW YORK, July 21 /PRNewswire-Asia-FirstCall/ -- American Oriental
Bioengineering, Inc. (NYSE:AOB), ("the Company" or "AOBO"), a
pharmaceutical company dedicated to improving health through the
development, manufacture and commercialization of a broad range of
prescription and over the counter ("OTC") products in China, today
announced that AOBO was honorably elected as one of the "Top 20
Most Competitive Public Pharmaceutical Companies in China." This
event was jointly organized by China's leading healthcare industry
associations, including the Chinese Pharmaceutical Enterprise
Association and its publication, Healthcare Executive Magazine, and
China's Center for Pharmaco-economics and Outcomes Research (CCPOR)
at Beijing University, where an awards ceremony was held today. The
20 listed companies were selected from 132 Chinese pharmaceutical
companies listed in Shanghai, Shenzhen, Hong Kong, Singapore, New
York or on NASDAQ, as of February of this year. The selection
criteria were based on the companies' management capabilities,
brand recognition, financial strength, resource accessibility and
quality of key team members. Mr. Tony Liu, Chairman and Chief
Executive Officer of American Oriental Bioengineering, commented,
"We are very honored to receive this recognition by the industry.
This award speaks to the strength of our brand value and
competitiveness in the changing environment. We will continue to
focus on creating greater value for investors." About American
Oriental Bioengineering, Inc. American Oriental Bioengineering,
Inc. is a China-based pharmaceutical company dedicated to improving
health through the development, manufacture and commercialization
of a broad range of prescription and over the counter products.
Statements made in this press release are forward-looking and are
made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks and
uncertainties that may cause actual results to differ materially
from those set forth in these statements. The economic,
competitive, governmental, technological and other factors
identified in the Company's filings with the Securities and
Exchange Commission, including the Form 10-K for the year ended
December 31, 2008, may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
DATASOURCE: American Oriental Bioengineering, Inc. CONTACT: Ashley
M. Ammon of Integrated Corporate Relations, Inc., +1-203-682-8208
Copyright
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jul 2023 to Jul 2024